AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Hoshizaki, you have to be comfortable with a quality, slower-growth industrial that leans heavily on disciplined capital allocation and income visibility rather than big upside surprises. The business has been growing steadily, with high quality earnings and improving margins, but the share price has lagged both the machinery sector and the broader Japanese market this year, which puts more emphasis on execution and capital returns as near term catalysts. The latest decision to lift the year-end dividend to ¥65 per share reinforces that shareholder-return story without obviously changing the earnings outlook, so it mainly strengthens the short term support from income-focused buyers rather than transforming the risk profile. The bigger watchpoints remain Hoshizaki’s relatively low return on equity, its premium valuation to peers, and board independence.
However, one governance issue may matter more than the higher dividend for long term investors. Hoshizaki's shares have been on the rise but are still potentially undervalued by 21%. Find out what it's worth.Explore 2 other fair value estimates on Hoshizaki - why the stock might be worth just ¥6693!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com